Eisai seeks UK Approval for Insomnia Therapy Lemborexant
Eisai has submitted lemborexant for regulatory review in the UK, aiming to expand treatment options for adults suffering from chronic insomnia and improve patients' daytime functioning.
Neurology | 04/07/2026 | By News Bureau
Lobe Sciences Establishes Wholly Owned Subsidiary Alera Pharma
Alera will be assigned the intellectual property rights focused on the company’s neurological assets and its new chemical entity Psilocin Mucate.
Neurology | 16/08/2024 | By Aishwarya | 951
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy